2022 World Conference on Lung Cancer (ePosters)-EP08.01-095. Efficacy and Safety of Combining Endostar with Camrelizumab plus Chemotherapy in Advanced NSCLC Patients: A Multi-Center Retrospective Study

EP08.01-095. Efficacy and Safety of Combining Endostar with Camrelizumab plus Chemotherapy in Advanced NSCLC Patients: A Multi-Center Retrospective Study

Back to course

Pdf Summary

A retrospective study was conducted to evaluate the efficacy and safety of combining the drugs Endostar, Camrelizumab, and chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). The study included 27 patients who had measurable disease and were negative for EGFR mutation or ALK fusion. The primary endpoint was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. <br /><br />The results showed that the combination treatment had promising efficacy and good tolerability. The ORR was 48% and the DCR was 85%, with one patient achieving a complete response and 12 patients achieving a partial response. The median PFS was 8.9 months, and the median OS was not reached. <br /><br />Subgroup analyses showed that patients who received four cycles of treatment had a higher ORR and DCR compared to those who received less than four cycles. The median PFS was significantly longer in patients who received four cycles of treatment compared to those who received less than four cycles. <br /><br />The most common adverse events were anemia and nausea/vomiting. One patient experienced immune-related hepatitis. <br /><br />In conclusion, the combination of Endostar, Camrelizumab, and chemotherapy showed promising efficacy and good tolerability in patients with advanced NSCLC. Patients who received four cycles of treatment had greater clinical benefit. This combination regimen may become a new treatment option for these patients, and further prospective studies are warranted.

Asset Subtitle

Lin Wu

Meta Tag

Speaker Lin Wu

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

retrospective study

efficacy

safety

Endostar

Camrelizumab

chemotherapy

non-small cell lung cancer

progression-free survival

adverse events

clinical benefit